In a nutshell This trial is investigating the effectiveness and side effects of nivolumab (Opdivo) with a dendritic cell vaccine for patients with multiple myeloma (MM). The main outcome of this study would be to see the number of patients that develop an allergic reaction to the treatment. This study is recruiting in Boston, MA, United...
Read MorePerformance status-2 – Symptomatic, 50 in bed Posts on Medivizor
Is RTXM83 as effective as rituximab for patients with diffuse large B-cell lymphoma?
In a nutshell This study compared RTXM83 to rituximab (Rituxan) to see if it is as effective and safe for patients with diffuse large B-cell lymphoma. This study concluded that RTXM83 is as effective and safe as rituximab. Some background Diffuse large B-cell lymphoma (DLBCL) is an aggressive type of non-Hodgkin’s lymphoma. This type...
Read MoreLooking for patients with breast cancer to trial a new chemotherapy drug combined with targeted therapy
In a nutshell This phase 2 trial will investigate the effects of tesetaxel combined with targeted therapy drugs in advanced breast cancer (BC). The main outcomes will be the overall response rate (ORR) and progression-free survival (PFS). This trial is recruiting in Boston, MA and East Setauket, NY. The details Some...
Read MoreLooking patients with metastatic non small cell lung cancer to trial a radiation treatment
In a nutshell This phase 2 trial will investigate the effectiveness of stereotactic body radiotherapy (SBRT) in patients with metastatic cancer. The main outcome will be progression-free survival (PFS; survival without the cancer getting worse). This trial is recruiting in multiple locations in New York and New Jersey, US. The details...
Read MoreSearching for patients with locally advanced non-small cell lung cancer to test a chemoradiotherapy regimen
In a nutshell This trial is examining the effectiveness and safety of standard chemoradiation vs a PET base chemoradiation combination in patients with non-small cell lung carcinoma (NSCLC). The main outcomes to be measured will be side effects and survival without cancer growing or spreading. The details A treatment option for...
Read MoreSearching for patients with recurrent multiple myeloma to test daratumumab
In a nutshell This phase 2 trial is evaluating how well daratumumab (Darzalex) works in treating patients with multiple myeloma (MM) that has come back after a stem cell transplant (SCT). The main outcome to be measured will be the number of patients who have a complete disappearance of all signs of cancer. This trial is recruiting in Houston,...
Read MoreSearching for patients to try a new treatment for multiple myeloma.
In a nutshell This study will investigate the effects of a new treatment, GSK2857916, in patients with multiple myeloma (MM). Overall response will be the main outcome measured. The details There are many treatment options for MM. However, some patients do not respond to treatments or relapse. New therapies are being developed for these patients....
Read MoreSearching for patients with to try a new therapy for multiple myeloma.
In a nutshell This study will investigate the effectiveness of daratumumab (Darzalex) added to VR-d regime [bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (Decadron)] versus VR-d alone in untreated multiple myeloma (MM). The development of minimal residual disease (MRD; a very small number of cancer cells remaining after treatment)...
Read MoreLooking for participants with colorectal cancer and liver metastasis to test a new cancer vaccine
In a nutshell This trial is examining the effectiveness of mFOLFOX6 (oxaliplatin, leucovorin, fluorouracil) and nivolumab (Opdivo) with and without a new cancer vaccine (CV301) for patients with colorectal cancer that has spread to the liver. The main outcome will be overall survival. This trial is being conducted in California and New Jersey,...
Read MoreEvaluating a new CAR-T cell therapy for patients with relapsed or refractory multiple myeloma
In a nutshell This study investigated the safety and effectiveness of a new chimeric antigen receptor (CAR) T cell therapy for relapsed or refractory (does not respond to treatment) multiple myeloma (MM). This study found that this cell therapy was effective, but it had significant side effects. Some background MM is a type of cancer of the...
Read MoreStereotactic body radiation therapy in patients with inoperable lung cancer
In a nutshell This study wanted to find out how well a treatment for lung cancer called stereotactic body radiation therapy works in patients with lung cancer that cannot be surgically removed. The study found that this treatment is effective in patients with lung cancer, and a higher dose of radiation is not any better than a lower dose. Some...
Read MoreThe socioeconomic impact of cachexia in elderly patients with advanced lung cancer
In a nutshell This study looked at the impact of cachexia (weakness or wasting of the body) in elderly patients with advanced non-small-cell lung cancer on disability, hospitalization and medical costs. The authors concluded that patients with cachexia had a higher risk of disability, longer hospital stays and higher medical costs, while being treated...
Read More